Clinical analysis of subthreshold micropulse laser for central serous chorioretinopathy

ZHAO Deng-Li; LI Sha; LONG Yan-ling; WANG Min; LIU Yong

doi:10.11659/jjssx.07E024132

您当前的位置：

首页 >

文章列表页 >

Clinical analysis of subthreshold micropulse laser for central serous chorioretinopathy

Clinical Research | 更新时间：2024-11-18

- Clinical analysis of subthreshold micropulse laser for central serous chorioretinopathy
- JOURNAL OF REGIONAL ANATOMY AND OPERATIVE SURGERY Vol. 33, Issue 11, Pages: 991-994(2024)
- 作者机构：
  
  陆军军医大学第一附属医院眼科，重庆 400038
- 作者简介：
- 基金信息：
- DOI：10.11659/jjssx.07E024132
  CLC： R774.1
- Published：25 November 2024，
  
  Received：24 July 2024，
- 稿件说明：
移动端阅览
赵邓丽,李莎,龙艳玲等.阈下微脉冲激光治疗中心性浆液性脉络膜视网膜病变的临床分析[J].局解手术学杂志,2024,33(11):991-994.

ZHAO Deng-Li,LI Sha,LONG Yan-ling,et al.Clinical analysis of subthreshold micropulse laser for central serous chorioretinopathy[J].JOURNAL OF REGIONAL ANATOMY AND OPERATIVE SURGERY,2024,33(11):991-994.
赵邓丽,李莎,龙艳玲等.阈下微脉冲激光治疗中心性浆液性脉络膜视网膜病变的临床分析[J].局解手术学杂志,2024,33(11):991-994. DOI： 10.11659/jjssx.07E024132.

ZHAO Deng-Li,LI Sha,LONG Yan-ling,et al.Clinical analysis of subthreshold micropulse laser for central serous chorioretinopathy[J].JOURNAL OF REGIONAL ANATOMY AND OPERATIVE SURGERY,2024,33(11):991-994. DOI： 10.11659/jjssx.07E024132.

摘要

目的

探索577 nm阈下微脉冲激光（SML）治疗中心性浆液性脉络膜视网膜病变（CSC）的短期疗效及安全性。

方法

回顾性分析2023年4月至2024年4月就诊于陆军军医大学第一附属医院的22例（24眼）CSC患者的临床资料，12眼为急性CSC，12眼为慢性CSC，均使用SML治疗。分析治疗前及治疗后1个月最佳矫正视力（BCVA）、黄斑中心凹视网膜厚度（CMT）、黄斑中心凹下脉络膜厚度（SFCT）、视网膜下液高度（SRFH）及微视野中心视敏度（CMS）的变化。观察治疗后1个月视网膜下液吸收情况及相关并发症发生情况。

结果

与治疗前相比，治疗后1个月CMT、SFCT、SRFH显著减小（

0.05）。治疗后1个月LogMAR BCVA及CMS较治疗前显著改善（

0.05）。治疗前CMS（

=-0.555，

=0.006）及LogMAR BCVA（

=0.439，

=0.032）与治疗前SRFH显著相关。SRFH变化与治疗前CMT（

=0.616，

=0.001）显著相关，但与治疗前SFCT（

=0.168，

=0.431）无相关性。治疗后1个月，有11眼视网膜下液完全吸收，12眼有不同程度吸收，1眼SRFH增加；未见相关不良反应发生。

结论

577 nm SML对CSC有良好的治疗效果，可显著改善黄斑区结构，提高中心视功能，并具有良好的安全性。

Abstract

Objective

To explore the short-term outcome and safety of 577 nm subthreshold micropulse laser （SML） in the treatment of central serous chorioretinopathy （CSC）.

Methods

The clinical data of 22 patients （24 eyes） with CSC who were admitted to First Affiliated Hospital of Army Medical University from April 2023 to April 2024 were retrospectively analyzed. The 12 eyes had acute CSC， the 12 eyes had chronic CSC， and all of them were treated with SML. The changes of best-corrected visual acuity （BCVA）， central macular thickness （CMT）， subfoveal choroidal thickness （SFCT）， subretinal fluid height （SRFH）， and central macular sensitivity （CMS） before treatment and 1 month after treatment were analyzed. The absorption of subretinal fluid 1 month after treatment and related complications were observed.

Results

Compared with those before treatment， the CMT， SFCT， and SRFH 1 month after treatment significantly declined （

0.05）. The LogMAR BCVA and CMS 1 month after treatment were significantly improved compared with those before treatment （

0.05）. The CMS （

=-0.555，

=0.006） and LogMAR BCVA （

=0.439，

=0.032） before treatment were significantly correlated with SRFH before treatment. The change of SRFH was significantly correlated with CMT before treatment （

=0.616，

=0.001）， but without correlation with SFCT before treatment （

=0.168，

=0.431）. One month after treatment， 11 eyes had complete absorption of subretinal fluid， 12 eyes had varying degrees of absorption， and 1 eye had an increase in SRFH. No related adverse reactions were observed.

Conclusion

The 577 nm SML has a good therapeutic effect on CSC， which can significantly improve the macular structure and central visual function， with good safety.

关键词

中心性浆液性脉络膜视网膜病变阈下微脉冲激光中心视功能

Keywords

central serous chorioretinopathysubthreshold micropulse lasercentral visual function

references

Fung AT， Yang Y， Kam AW. Central serous chorioretinopathy： a review［J］.Clin Exp Ophthalmol，2023，51（3）：243-270.doi： 10.1111/ceo.14201http://dx.doi.org/10.1111/ceo.14201.

Kaye R， Chandra S， Sheth J， et al. Central serous chorioretinopathy： an update on risk factors， pathophysiology and imaging modalities［J］. Prog Retin Eye Res，2020，79：100865.doi：10.1016/j.preteyeres.2020.100865http://dx.doi.org/10.1016/j.preteyeres.2020.100865.

Sartini F， Figus M， Nardi M， et al. Non-resolving， recurrent and chronic central serous chorioretinopathy： available treatment options［J］.Eye （Lond），2019，33（7）：1035-1043.doi：10.1038/s41433-019-0381-7http://dx.doi.org/10.1038/s41433-019-0381-7.

van Rijssen TJ， van Dijk EHC， Yzer S， et al. Central serous chorioretinopathy： towards an evidence-based treatment guideline［J］.Prog Retin Eye Res，2019，73：100770.doi：10.1016/j.preteyeres.2019.07.003http://dx.doi.org/10.1016/j.preteyeres.2019.07.003.

Sirks MJ， van Dijk EHC， Rosenberg N， et al. Clinical impact of the worldwide shortage of verteporfin （Visudyne（R）） on ophthalmic care［J］. Acta Ophthalmol，2022，100（7）：e1522-e1532. doi： 10.1111/aos.15148http://dx.doi.org/10.1111/aos.15148.

Sirks MJ，Subhi Y，Rosenberg N，et al.Perspectives and update on the global shortage of verteporfin （Visudyne®）［J］.Ophthalmol Ther，2024，13（7）：1821-1831.doi：10.1007/s40123-024-00952-9http://dx.doi.org/10.1007/s40123-024-00952-9.

Iovino C， Iodice CM， Pisani D， et al. Yellow subthreshold micropulse laser in retinal diseases： an in-depth analysis and review of the literature［J］.Ophthalmol Ther， 2023，12（3）：1479-1500. doi：10.1007/s40123-023-00698-whttp://dx.doi.org/10.1007/s40123-023-00698-w.

Su D， Hubschman JP. A review of subthreshold micropulse laser and recent advances in retinal laser technology［J］. Ophthalmol Ther，2017，6（1）：1-6. doi： 10.1007/s40123-017-0077-7http://dx.doi.org/10.1007/s40123-017-0077-7.

Li X，Long H，Hu Q.Efficacy of subthreshold micropulse laser for chronic central serous chorioretinopathy： a meta-analysis［J］.Photodiagnosis Photodyn Ther，2022，39：102931.doi：10.1016/j. pdpdt.2022.102931http://dx.doi.org/10.1016/j.pdpdt.2022.102931.

Zhou L， Lai K， Jin L， et al. Subthreshold micropulse laser vs. conventional laser for central serous chorioretinopathy： a randomized controlled clinical trial［J］. Front Med （Lausanne），2021，8：682264. doi： 10.3389/fmed.2021.682264http://dx.doi.org/10.3389/fmed.2021.682264.

Deng K， Gui Y， Cai Y， et al. Changes in the foveal outer nuclear layer of central serous chorioretinopathy patients over the disease course and their response to photodynamic therapy［J］. Front Med （Lausanne），2021，8：824239. doi： 10.3389/fmed.2021.824239http://dx.doi.org/10.3389/fmed.2021.824239.

Gawecki M. Micropulse laser treatment of retinal diseases［J］. J Clin Med，2019，8（2）：242. doi： 10.3390/jcm8020242http://dx.doi.org/10.3390/jcm8020242.

Arora S，Sridharan P，Arora T，et al.Subthreshold diode micropulse laser versus observation in acute central serous chorioretinopathy［J］. Clin Exp Optom，2019，102（1）：79-85. doi：10.1111/cxo.12818http://dx.doi.org/10.1111/cxo.12818.

Guo JJ，Li XJ，Wan JJ.Efficacy and safety of subthreshold micropulse laser in the treatment of acute central serous chorioretinopathy［J］.Int J Ophthalmol，2023，16（6）：921-927.doi：10.18240/ijo.2023.06.14http://dx.doi.org/10.18240/ijo.2023.06.14.

吴妍，陈放，李喆. 微脉冲激光治疗慢性中心性浆液性脉络膜视网膜病变的短期效果观察［J］.中华眼外伤职业眼病杂志，2022，44（12）：881-888.doi：10.3760/cma.j.cn116022-20220615-00251http://dx.doi.org/10.3760/cma.j.cn116022-20220615-00251.

Fasler K， Turgut F， Gunzinger JM， et al. Efficacy of subthreshold micropulse laser for central serous chorioretinopathy［J］. Klin Monbl Augenheilkd，2024，241（4）：489-495.doi：10.1055/a-2229-2298http://dx.doi.org/10.1055/a-2229-2298.

Zheng F， He J， Su Z， et al. OCT biomarkers related to subthreshold micropulse laser treatment effect in central serous chorioretinopathy［J］. BMC Ophthalmol，2022，22（1）：252.doi：10.1186/s12886-022-02472-1http://dx.doi.org/10.1186/s12886-022-02472-1.

Oribio-Quinto C， Alarcon-Garcia AD， Enriquez-Fuentes J， et al. Functional and anatomical results of subthreshold micropulse laser as rescue treatment for central serous chorioretinopathy after verteporfin shortage［J］. Photodiagnosis Photodyn Ther，2024，49：104295.doi：10.1016/j.pdpdt.2024.104295http://dx.doi.org/10.1016/j.pdpdt.2024.104295.

Maruko I， Iida T， Sugano Y， et al. Subfoveal choroidal thickness in fellow eyes of patients with central serous chorioretinopathy［J］. Retina，2011，31（8）：1603-1608.doi：10.1097/IAE.0b013e31820f4b39http://dx.doi.org/10.1097/IAE.0b013e31820f4b39.

Kiraly P，Smrekar J，Mekjavic PJ.Visual function during and after an acute central serous chorioretinopathy episode［J］.Doc Ophthalmol，2022，145（1）：27-35.doi：10.1007/s10633-022-09875-xhttp://dx.doi.org/10.1007/s10633-022-09875-x.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

No data

Related Author

No data

Related Institution

No data

⁰